VIRAL RESPONSE SYSTEMS - FULL-PAGE CHICAGO TRIBUNE: 'OUR CRIME IS REDUCING MEDICAL COSTS'
VIRAL RESPONSE SYSTEMS - FULL-PAGE CHICAGO TRIBUNE: 'OUR CRIME IS REDUCING MEDICAL COSTS' GREENWICH, Conn., Dec. 13 /PRNewswire/ -- Viral Response Systems, Inc. (NASDAQ: VRSI) today issued a statement in connection with its full-page advertisement in the Chicago Tribune criticizing Washington for allowing former high ranking officials of the FDA, in the employ of major drug companies, to initiate a federal vendetta against the safe and effective Viralizer with ViraSpray, sold for the relief of the symptoms of colds, allergies, sore throat and sinusitis. Viral Response, which recently exhibited the Viralizer at the annual meeting of the American College of Allergy and Immunology, said the ad had been refused by the New York Times. The statement: Viral Response Systems accuses the New York Times of arrogant cowardice, for rejecting the same advertisement. VRS alleges that on two occasions the New York Times ran false and harmful Viralizer articles, parroting the untruths of others and now refuses to allow Viralizer to set the record straight in the Times, for fear of intellectual embarrassment. Viral Response points out chapter and verse, where the FDA blatantly misled the media and subsequently the American people about non-existent Viralizer consumer complaints and other matters. Viralizer illustrates via actual consumer and physician letters to the commissioner of the Food and Drug Administration and the chairman of the Federal Trade Commission, dramatic reductions in medical care costs and pain and suffering, especially for the elderly, achieved from the relief provided by Viralizer usage. President Robert S. Krauser said Viralizer's real crime is medical cost savings. The advertisement also cites double-blind multi-center clinical studies which demonstrate the safety and efficacy of the Viralizer with ViraSpray for the relief of upper respiratory symptoms. Viral Response indicates that after four years of marketing over 200,000 Viralizers and 200,000 ViraSpray refill packages, VRS has received tens of thousands of enthusiastic consumer comments with not a single, solitary consumer complaint on file at the Better Business Bureau, of which the company is an invited member. In view of numerous consumer reports of substantial medical cost savings, Viralizer has expanded its money-back guarantee to include not only the most satisfying relief of upper respiratory symptoms, but also annual savings of $300 in family medical costs. Viralizer warns the American people to "Never underestimate the power of the $650 billion medical/industrial complex and Washington's ruling class mentality" and that "The nation's $650 billion per year medical bill may be dangerous to your health." VRS also warns the American people that the FDA ignored its own expert panel by not requiring the label warning: "Do not exceed recommended dosage because severe liver damage may occur," on Vick's Nyquil and similar alcohol/acetaminophen products. -0- 12/13/91 /CONTACT: Robert S. Krauser, president of Viral Response Systems, 203-661-1550/ (VRSI) CO: Viral Response Systems, Inc. ST: Connecticut IN: MTC SU:
SM-OS -- NY017 -- 2333 12/13/91 11:21 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 13, 1991|
|Previous Article:||DELMARVA POWER RECEIVES 27 POWER SUPPLY PROPOSALS|
|Next Article:||FORD MOTOR COMPANY REPORTS U.S. SALES|